SUBSCRIBE
SUBSCRIBE
News   Drug Development

Alnylam Pharmaceuticals, Cubist Pharmaceuticals, Inc. Say Respiratory Drug Meets Main Goal

June 8, 2009 | 
1 min read
Bookmark and Share

Reuters -- Alnylam Pharmaceuticals Inc (ALNY.O) and Cubist Pharmaceuticals Inc (CBST.O) said their experimental drug to treat respiratory infection met the main goal in a mid-stage study.

Clinical research Phase II Phase III
Alnylam Pharmaceuticals
MORE ON THIS TOPIC
Exclusive magazine sketch collage image of happy businesswoman businessman stand question mark strategy ceo magnifier search job.
Neuropsychiatric disorders
Otsuka, Lundbeck’s PTSD Bid for Rexulti Hits Speedbump as FDA Questions Efficacy
July 17, 2025
 · 
2 min read
 · 
Tristan Manalac
IN PARTNERSHIP WITH EVOTEC
Webinar: Pharma Industry in Crisis
July 16, 2025
 · 
1 min read
 · 
BioSpace Insights
Goal disorientation and lack of vision. Inability to set the right business objectives. Failure to achieve the objectives. Missing the unrealistic and inaccurate company goals.
Rare diseases
AstraZeneca’s Amyloidosis Asset Stumbles in Late-Stage Trials
July 16, 2025
 · 
1 min read
 · 
Dan Samorodnitsky
Wood block with healthcare medical icon on blue background. Health care insurance concept
Infectious disease
Gilead, GSK/ViiV, Merck Present New HIV PrEP Frontiers at IAS25
July 15, 2025
 · 
4 min read
 · 
Tristan Manalac